The two-part production system is proven to yield high-quality proteins from GS-CHO cell lines, a prevalent mammalian host cell for protein production
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
Advances clinical research capabilities with leading regulatory grade registries platform
The €70 million investment will allow the large-scale manufacturing of high-purity reagents for quality control and testing for biopharma customers, increasing annual output by several thousand tons
As Caeregen’s CDMO partner for CTR-107, Wacker Biotech will produce drug substance at its site in Halle, Germany, and complete clinical trial drug product production at its site in Amsterdam, the Netherlands
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12
The booster vaccine can be administered safely to individuals who have received two doses of either Covaxin or Covishield
This trial is a multi-national, phase 2/3, open-label, randomized, controlled clinical study of utidelone injectable
Investment enables development of revolutionary multi-omic platform using super-resolution imaging technology for earlier disease detection and accelerated discovery of therapeutics
Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease
Subscribe To Our Newsletter & Stay Updated
